MedX Health Corporation (CVE:MDX) has announced a distribution agreement with VidaCeuticals Health Products Inc to improve accessibility to potentially life-saving scans for skin cancer.
The Mississauga, Ontario-based company offers a telemedicine platform, utilizing its SIAscopy technology. This proprietary innovation is also part of its SIAMETRICS system, a research tool used to assess treatment effectiveness of a variety of skin conditions, including burns.
MedX also recently announced a memorandum of understanding with Empower Clinics Inc.(CSE:CBDT) (OTCQB:EPWCF) to pilot its DermSecure screening platform.
WATCH: MedX Health to provide its DermSecure Screening Platform for two Ontario-based Empower Clinics
“With only about 500 dermatologists available to serve over 37 million Canadians, the wait times to see a dermatologist in-person can be anywhere from five months to one year,” Sylvain Desjeans, MedX’s chief revenue officer said in a statement.
“The COVID-19 pandemic has nearly doubled the average wait period. We know that early detection of melanoma greatly increases the patient’s survival rate and reduces the cost to the healthcare system. Increasing accessibility to scanning through partnering with VidaCeuticals and their deep network of clinic partners will help us work towards early skin cancer detection.”
The partnership with VideCeuticals will see MedX’s integrated skin assessment teledermatology platform offered at four clinics in Ontario beginning in late June, with plans for a broader market roll-out in Canada and the US later this year. The initial four clinics will be located in London, Ottawa, Port Elgin and Sarnia.
MedX said alignment on company values and a passion to save lives drew VidaCeuticals Health Products to connect with it to support a strategic and aggressive distribution plan to reach more North Americans with its technology, which also includes the DermSecure cloud-based telemedicine platform.
“We have shared values and a passion for finding solutions that are easy to access and that ultimately improve and save lives, avoiding unnecessary health impacts on families and communities,” VidaCeuticals Health Products MD Jean-Guy Bourguignon said.
Contact the author: stephen.gunnion@proactiveinvestors.com